Loading...
XSTOIVACC
Market cap6mUSD
Dec 23, Last price  
1.00SEK
1D
-0.99%
1Q
-72.22%
IPO
-85.60%
Name

Intervacc AB

Chart & Performance

D1W1MN
XSTO:IVACC chart
P/E
—
P/S
9.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.64%
Rev. gr., 5y
-25.79%
Revenues
8m
-17.23%
794,40078,086,67162,830,77655,575,48848,004,13635,600,00012,139,0004,780,0005,241,0009,684,0008,015,000
Net income
-103m
L+60.31%
-2,285,0579,323,666138,077-6,806,616-12,766,582-27,492,000-27,892,000-25,601,000-29,375,000-64,158,000-102,852,000
CFO
-46m
L-34.33%
00-19,085,339-4,199,997-19,158,104-4,033,000-2,770,000-20,081,000-25,463,000-69,790,000-45,834,000
Earnings
Feb 13, 2025

Profile

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
URL
http://intervacc.se/
IPO date
Apr 07, 2017
Employees
15
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
8,015
-17.23%
9,684
84.77%
5,241
9.64%
Cost of revenue
39,366
47,746
13,646
Unusual Expense (Income)
NOPBT
(31,351)
(38,062)
(8,405)
NOPBT Margin
Operating Taxes
11,388
3
92
Tax Rate
NOPAT
(42,739)
(38,065)
(8,497)
Net income
(102,852)
60.31%
(64,158)
118.41%
(29,375)
14.74%
Dividends
Dividend yield
Proceeds from repurchase of equity
103,506
6,120
BB yield
-26.82%
-0.41%
Debt
Debt current
39
139
211
Long-term debt
142
183
222
Deferred revenue
Other long-term liabilities
Net debt
(88,160)
126,955
67,370
Cash flow
Cash from operating activities
(45,834)
(69,790)
(25,463)
CAPEX
(56)
(6,132)
(23,206)
Cash from investing activities
(2,107)
(6,132)
(23,127)
Cash from financing activities
90,583
5,909
50
FCF
(29,275)
(51,669)
(8,928)
Balance
Cash
88,341
45,699
115,712
Long term investments
(172,332)
(182,649)
Excess cash
87,940
Stockholders' equity
151,473
(42,888)
20,564
Invested Capital
150,172
293,369
308,685
ROIC
ROCE
EV
Common stock shares outstanding
60,963
57,908
57,753
Price
6.33
-75.65%
26.00
-51.13%
53.20
0.76%
Market cap
385,896
-74.37%
1,505,609
-51.00%
3,072,443
7.51%
EV
297,736
1,632,564
3,139,813
EBITDA
(6,752)
(17,204)
(2,253)
EV/EBITDA
Interest
133
125
74
Interest/NOPBT